Alan Moss

Alan Moss

Auto-generated profile, based on publicly available information

Alan Moss

Crohn’s & Colitis Foundation , New York, NY 10017

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
KNKavinderjit S Nanda
Kavinderjit S Nanda
ACAdam S Cheifetz
Adam S Cheifetz
AMAlan C Moss
Alan C Moss
Rapies. The objective of this study was to perform a systematic review and meta-analysis of studies that reported clinical outcomes and IFX levels according to patients’ ATI status. METHODS: MEDLINE, Web of Science, CINAHL, Scopus, and EMBASE were searched for eligible studies. Quality assessment was undertaken using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria. Raw data from studies meeting inclusion criteria was pooled for meta-analysis of effect estimates. Sensitivity analysis was performed for all outcomes. Funnel plot was performed to assess for publication bias. RESULTS: Thirteen studies met the inclusion criteria, and reported results in 1,378 patients with IBD. All included studies had a high risk of bias in at least one quality domain. The pooled risk ratio (RR) of loss of clinical response to IFX in patients with IBD who had ATIs was 3.2 (95% confidence interval (CI): 2.0–4.9,P<0.0001), when compared with patients without ATIs. This effect estimate was predominantly based on data from patients (N=494) with Crohn's disease (RR: 3.2, 95% CI: 1.9–5.5,P<0.0001). Data only from patients with ulcerative colitis (n=86) exhibited a non-significant RR of loss of response of 2.2 (95% CI: 0.5–9.0,P=0.3) in those with ATIs. Heterogeneity existed between studies, in both methods of ATI detection, and clinical outcomes reported. Three studies (n=243) reported trough serum IFX levels according to ATI status; the standardized mean difference in trough serum IFX levels between groups was −0.8 (95% CI −1.2, −0.4,P<0.0001). A funnel plot suggested the presence of publication bias. CONCLUSIONS: The presence of ATIs is associated with a significantly higher risk of loss of clinical response to IFX and lower serum IFX levels in patients with IBD. Published studies on this topic lack uniform reporting of outcomes. High risk of bias was present in all the included studies....

1 September 2010 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
GLGarrett Lawlor
Garrett Lawlor
AMAlan C. Moss
Alan C. Moss

1 September 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
Byron VaughnByron Vaughn
Byron Vaughn
Tommi VatanenTommi Vatanen
Tommi Vatanen
JAJessica R. Allegretti
Jessica R. Allegretti
ABAiping Bai
Aiping Bai
RXRamnik J. Xavier
Ramnik J. Xavier
AMAlan C. Moss
Alan C. Moss
Background. The microbiota in the lumen of patients with Crohn's disease (CD) is characterized by reduced diversity, particularly Firmicutes and Bacteroidetes.

1 November 2014 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
Byron VaughnByron Vaughn
Byron Vaughn
MMManuel Martinez-Vazquez
Manuel Martinez-Vazquez
VPVilas R. Patwardhan
Vilas R. Patwardhan
AMAlan C. Moss
Alan C. Moss
WSWilliam J. Sandborn
William J. Sandborn
ACAdam S. Cheifetz
Adam S. Cheifetz
Background. Infliximab (IFX) is effective in the treatment of inflammatory bowel disease; however, the effect is often not durable. It is unknown if proactive t

1 April 2007 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
AMAlan C. Moss
Alan C. Moss
EMEva Morris
Eva Morris
JLJan Leyden
Jan Leyden
PMPadraic MacMathuna
Padraic MacMathuna

1 December 2007 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AMAlan C. Moss
Alan C. Moss
EMEva Morris
Eva Morris
JLJan Leyden
Jan Leyden
PMPadraic MacMathuna
Padraic MacMathuna
A variety of stent designs has been studied for endoscopic stenting of the bile duct in patients with malignant biliary obstruction. Although metal stents are associated with longer patency, their costs are significantly higher than plastic stents. To compare clinical outcome and cost-effectiveness of endoscopic metal and plastic stents for malignant biliary obstruction by a systematic review and meta-analysis of all randomized controlled trials in this area. We conducted searches to identify all randomized controlled trials in any language from 1966 to 2006 using electronic databases and hand-searching of conference abstracts. Meta-analysis was performed with RevMan software [Review Manager (RevMan) version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003]. Seven randomized controlled trials were identified that met the inclusion criteria, and 724 participants were randomized to either metal or plastic endoscopic stents. No significant difference between the two stent types in terms of technical success, therapeutic success, 30-day mortality or complications was observed. Metal stents were associated with a significantly less relative risk (RR) of stent occlusion at 4 months than plastic stents [RR, 0.44; 95% confidence interval (CI) 0.3, 0.63; P<0.01]. The overall risk of recurrent biliary obstruction was also significantly lower in patients treated with metal stents (RR, 0.52; 95% confidence interval 0.39, 0.69; P<0.01). The median incremental cost-effectiveness ratio of metal stents was $1820 per endoscopic retrograde cholangiopancreatography prevented. Endoscopic metal stents for malignant biliary obstruction are associated with significantly higher patency rates than plastic stents as early as 4 months after insertion. Metal stents will be cost-effective if the unit cost of additional endoscopic retrograde cholangiopancreatographies per patient exceeds $1820.